Actinium Pharmaceuticals CSO Kamal Adeela files initial beneficial ownership statement
ATNM•Initial ownership filing
- Chief Scientific Officer Kamal Adeela filed an initial Actinium Pharmaceuticals ownership report showing 213,648 common shares.
- The filing also lists stock options for 120,000 shares with a USD 1 exercise price.
